Rezatapopt Posts 48% ORR in Pivotal Ovarian Analysis; PMV Pharma Targets Q1 2027 NDA
PMVP sits 33% above its 52-week low of $0.66 on elevated volume (6.0× avg).
Summary
PMV Pharma reported the pivotal Phase 2 primary analysis of rezatapopt, showing a 48% confirmed response rate and 10.4-month median duration of response in 65 platinum-resistant ovarian cancer patients, plus a 36% ORR across 168 patients in eight tumor types. An NDA for accelerated approval is planned for Q1 2027.
Key Events · Product Development and Regulatory · PMVP
-
Pivotal Ovarian Cohort Shows 48% ORR
In the 65-patient primary analysis population of platinum-resistant/refractory ovarian cancer, investigator-assessed confirmed ORR was 48% (31/65, one CR and 30 PRs), with a 10.4-month median duration of response and an 83% disease control rate.
-
Broad Activity Across 168 Patients
Across all cohorts, the overall population showed a 36% ORR (61/168, including four CRs) and an 8.1-month median duration of response; by cohort, ORRs were ovarian 45% (45/101), endometrial 45% (5/11), lung 21% (4/19), breast 17% (3/18) and other solid tumors 21% (4/19).
-
Biomarker Confirms On-Target Effect
Of 50 patients with ctDNA data, 90% (45/50) achieved at least a 50% reduction in TP53 Y220C variant allele frequency within 3-6 weeks of starting treatment.
-
Manageable Safety, 6% Discontinuation
Treatment-related adverse events were mostly Grade 1 or 2, individual Grade 3 TRAE rates were at or below 7.2%, and 11 patients (6%), including seven ovarian patients, discontinued due to TRAEs.
Analysis · PMVP · Life Sciences
The dataset PMV Pharma intends to file on is now in hand: the primary analysis of the registrational Phase 2 PYNNACLE trial. In 65 platinum-resistant/refractory ovarian cancer patients — a group with few remaining options after a median of four prior lines of therapy — rezatapopt delivered a 48% confirmed response rate, a 10.4-month median duration of response and an 83% disease control rate. Activity was not confined to one cohort: the 36% ORR across all 168 evaluable patients in eight tumor types, together with a 90% ctDNA response rate, points to on-target mechanism rather than a single-cohort fluke. Safety looks manageable, with individual Grade 3 treatment-related events at or below 7.2% and 6% of patients discontinuing for toxicity. Management reiterated an NDA submission for accelerated approval in Q1 2027, and that filing is now the single event determining whether this asset has commercial value. The risk is concentrated there: accelerated approval would rest on this single-arm data, and the company had $108.5 million in cash as of the last quarterly report, so the filing timeline and any FDA pushback matter more than the response rate itself.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMVP was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.2M. The 52-week trading range was $0.66 to $1.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.